Glycerin
drugOn this page
Also known as E-422E422FEMA NO. 2525GlicerolGlycerin component of monoctanoin dGlycerin component of procalamineanhydrousGlycerinumGlycerolGlycerol 85%GlycerolumGlycogelatinINS NO.422INS-422KeybellsM 314429NirolexNSC-9230PZN 7474853
Summary
Glycerin (CHEMBL692) is an approved small molecule (ATC A06AX01); indicated across 15 conditions including constipation disorder and decubitus ulcer.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A06AX01 (+1 more)
- Indications: 15 conditions
- Clinical trials: 40
- Chemistry: 92.09 Da · C3H8O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL692 |
| Name | Glycerin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 753 |
| ChEBI | CHEBI:17522 |
| ATC | A06AX01, A06AG04 |
| Molecular formula | C3H8O3 |
| Molecular weight | 92.09 |
| InChIKey | PEDCQBHIVMGVHV-UHFFFAOYSA-N |
SMILES: C(C(CO)O)O
IUPAC name: propane-1,2,3-triol
ChEBI definition: A carbohydrate that is an acyclic polyol having the general formula HOCH2[CH(OH)]nCH2OH (formally derivable from an aldose by reduction of the carbonyl group).
Also known as: E-422, E422, FEMA NO. 2525, Glicerol, Glycerin, Glycerin component of monoctanoin d, Glycerin component of procalamine, anhydrous, Glycerinum, Glycerol, Glycerol 85%, Glycerolum
Patent coverage: 883,978 distinct patent families (2,378,404 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, Aldehyde dehydrogenase 1A1.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| LMNA | 6.45 | Potency | 354.8 | nM | CHEMBL_ACT_3647493 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
15 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| constipation disorder | 4 | MONDO:0002203 | HP:0002019 |
| decubitus ulcer | 4 | MONDO:0004646 | EFO:0007067 |
| hemorrhoid | 4 | MONDO:0004872 | EFO:0009552 |
| allergic disease | 4 | MONDO:0005271 | MONDO:0005271 |
| atopic conjunctivitis | 3 | MONDO:0005642 | EFO:0007141 |
| bacterial meningitis | 3 | MONDO:0006670 | EFO:1000831 |
| acute pancreatitis | 3 | MONDO:0006515 | EFO:1000652 |
| otitis media | 3 | MONDO:0005441 | MONDO:0024330 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| sarcoma | 2 | MONDO:0005089 | EFO:0000691 |
| dry eye syndrome | 2 | MONDO:0006733 | EFO:1000906 |
| refractive error | 2 | MONDO:0004892 | HP:0000539 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 40.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 23 |
| PHASE4 | 10 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05821309 | PHASE4 | RECRUITING | Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen |
| NCT07226739 | PHASE4 | NOT_YET_RECRUITING | Comprehensive Toileting Program |
| NCT00779792 | PHASE4 | UNKNOWN | Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation |
| NCT01271855 | PHASE4 | COMPLETED | Assessing Maternal Post-partum Pain With Suppositories |
| NCT02797067 | PHASE4 | COMPLETED | Rectal Indomethacin to Prevent Post ESWL-pancreatitis |
| NCT02833415 | PHASE4 | COMPLETED | Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging |
| NCT02936830 | PHASE4 | COMPLETED | Effectiveness of Nanohydroxyapetite Paste on Reducing Dentin Hypersensitivity |
| NCT03355326 | PHASE4 | TERMINATED | Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis |
| NCT03657407 | PHASE4 | COMPLETED | B&O for TLH Post-operative Pain and Nausea |
| NCT06491394 | PHASE4 | COMPLETED | Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats |
| NCT05660447 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR |
| NCT00619203 | PHASE3 | COMPLETED | Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis |
| NCT03197922 | PHASE3 | COMPLETED | Treatment of Encopresis in Children With Autism Spectrum Disorders |
| NCT06792500 | PHASE1/PHASE2 | RECRUITING | A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber’s Hereditary Optic Neuropathy-Plus (LHON-Plus) |
| NCT02624661 | PHASE1/PHASE2 | TERMINATED | Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique |
| NCT01412658 | PHASE1 | COMPLETED | Clinical Safety of a Novel Milk Protein Peptide |
| NCT05497934 | PHASE1 | WITHDRAWN | The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear |
| NCT03935139 | Not specified | RECRUITING | Monitoring of the Bone Free Flaps With Microdialysis |
| NCT06048614 | Not specified | RECRUITING | Saline Enema Administration in Meconium Obstruction of Prematurity and Impact on the Resolution, Feeds, Microbiome, and Gut-brain Axis. |
| NCT06955130 | Not specified | NOT_YET_RECRUITING | Lactate and Glycerol Contribution to Gluconeogenesis |
| NCT07406425 | Not specified | NOT_YET_RECRUITING | Evaluation of Efficacy of Coconut Oil Mouth Care for Non-autonomous Hospitalised Elderly People. |
| NCT00005889 | Not specified | UNKNOWN | Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion |
| NCT00152945 | Not specified | COMPLETED | Determining the Responsiveness of Intestinal Lipoprotein Production to an Elevation of Plasma Free Fatty Acids |
| NCT00333671 | Not specified | COMPLETED | Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema) |
| NCT00681265 | Not specified | COMPLETED | Tear Film Break-up Time After Instillation of Artificial Tears |
| NCT00786487 | Not specified | COMPLETED | Training Effects on Skeletal Muscle Fatty Acid Metabolism |
| NCT00932477 | Not specified | COMPLETED | Safety and Tolerability of Artificial Tears in Dry Eye Subjects |
| NCT01010282 | Not specified | COMPLETED | Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects |
| NCT01746511 | Not specified | COMPLETED | Glycerin Suppositories to Reduce Jaundice in Premature Infants |
| NCT01799629 | Not specified | TERMINATED | Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial |
| NCT02149407 | Not specified | UNKNOWN | Glycerin Suppositories for Treatment of Feeding Intolerance in Preterm Infants |
| NCT02153606 | Not specified | UNKNOWN | Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial |
| NCT02383758 | Not specified | COMPLETED | An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders |
| NCT02517307 | Not specified | COMPLETED | Fatty Acid Oxidation Defects and Insulin Sensitivity |
| NCT02585791 | Not specified | TERMINATED | Evaluation of Acute and Subacute Effects of Nicotine Free Electronic Cigarette(NCFE) Vapors |
| NCT03157583 | Not specified | COMPLETED | A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations |
| NCT03400969 | Not specified | UNKNOWN | Effectiveness of Three Different Oral Moisturizers in Palliative Care Patients. |
| NCT05057351 | Not specified | COMPLETED | A Controlled Study to Evaluate the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis |
| NCT05295836 | Not specified | COMPLETED | Effects of Acute Glycerol Ingestion on Performance, Metabolic and Biochemical Markers in International Athletes |
| NCT05660681 | Not specified | COMPLETED | Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).